Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)
| EXCHANGE / SYMBOL | OTCBB / ORMP |
| CURRENT PRICE | $1.10 (as of June 12, 2006) |
| SHARES OUTSTANDING | 18.5 MILLION |
| MARKET CAP | $20.3 MILLION |
| 52-WEEK RANGE | $.31 - $1.10 |
About Oramed Pharmaceuticals
Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of type 1 and 2 diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
Company Highlight
- Demand for alternative insulin delivery technologies is rising.
- Type 2 diabetes therapy market is expected to exceed US $15.3 billion in 2013.
- The Research team is made up of experts involved in the development of insulin tablets and also in the conversion of other polypeptides including vaccinations and other hormones into per-oral forms g. tablets.
- Effectiveness of insulin tablets is already proven successful on trials on animals at Hadassah University Hospital in Jerusalem.
- Oral insulin tablets enable the delivery of insulin in a more physiological manner than by injection.
Management Team
Dr. Miriam Kidron, Chairperson & Founder
Dr. Miriam Kidron is a pharmacologist and a biochemist with a PhD in biochemistry. From 1990 to the present time, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. She was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations.
Dr. Hanoch Bar-On, Director
Dr. Bar-On is a professor of internal medicine and former head of the Diabetes Unit at Hadassah Medical Organization (Israel). He was also a visiting associate professor in Internal Medicine at Stanford University Medical School and Albert Einstein College of Medicine. Dr. Bar-On is a member of the American, European and Israel Diabetes Associations.
Mr. Nadav Kidron, CEO
Mr. Kidron is an entrepreneur whose expertise includes senior executive roles in a wide range of industries. Among his achievements, Kidron co-founded Mabool.com, an Internet start-up in the e-auction business that successfully raised US $1.5 million. He graduated from Bar-Ilan University Israel with a Bachelor of Law degree.
Mr. George Drazenovic, CFO
Mr. Drazenovic has over 10 years of experience in accounting, financial management and financial reporting. Most recently, he was the CFO for a public energy technology company with a market capitalization in excess of US $60 million. Mr. Drazenovic is a CFA, CGA and holds an MBA from the University of Notre Dame (US) and a BA in Economics from the University of British Columbia (Canada).
Nadav Kidron, Esq.
2 Elza Street, Jerusalem, Israel 93706
011 972-54-790 9058
011 972-2-679 2336 (FAX)
Oramed Pharmaceuticals, Inc.
Vinisha Agnihotri
Investor Relations
(646) 467-2252
info@oramedpharma.com
http://www.oramedpharma.com
